Stories about therapy
- more
Euretina: OD-OS presents Navilas® Pro as an affordable entry to the digital ecosystem of navigated laser
moreSTADA expands specialty footprint through acquisition of innovative therapy for treating advanced Parkinson's disease
One documentmoreDEBIOPHARM LAUNCHES TRILYNX - A LARGE-SCALE PHASE III CLINICAL TRIAL TO FURTHER EVALUATE XEVINAPANT IN THE TREATMENT OF HEAD & NECK CANCER
moreSysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
moreSysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing
moreDebiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer
moreElse Kröner-Fresenius-Stiftung
Groundbreaking Gene Therapies for Hereditary Diseases / Alessandro Aiuti, a physician and research scientist from Milan, receives the Else Kröner Fresenius Prize for Medical Research 2020 endowed with 2.5 million euros
moreElastrin Therapeutics develops new approach against "Inflammatory Storm" that kills most Corona patients
moreFirst Digital Health Osteoarthritis Wearable Glove System Starts Pre-launch Pilot Trial Series & Medical Tests
moreMerck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
moreKyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome
moreTwo-pronged approach - Novel combined therapy tackles excess fatty tissue
moreTechnische Universität München
Test predicts outcome of hay fever therapies
moreAccuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018
moreSysmex Inostics' OncoBEAM(TM) liquid biopsy technology demonstrates utility for clinical management of melanoma patients undergoing treatment with targeted therapy and immune checkpoint inhibitors
moreKyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome
moreAstellas Pharma Europe Limited
Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine
moreAstellas Pharma Europe Limited
New Class of Treatment for Overactive Bladder Demonstrates Efficacy and Tolerability Across Three Separate Studies
more
1